When was Cellipont founded?

Cellipont was founded in 2002 and raised its 1st funding round 21 years after it was founded.

Where is Cellipont located?

Cellipont is headquartered in Poway, United States.

How many employees does Cellipont have?

As of Apr 30, 2026, the latest employee count at Cellipont is 101.

Is Cellipont a funded company?

Cellipont is a funded company, having raised a total of $***** in its 1st and only funding round, a Conventional Debt round on Mar 21, 2023.

When was the latest funding round of Cellipont?

Cellipont's latest funding was a $***** Conventional Debt round on Mar 21, 2023, with participation from 1 investor.

Where does Cellipont rank among its competitors?

Cellipont ranks 18th amongst 97 active competitors, of which 21 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Pluri, which secured $2.5M in Mar, 2026.

Who are the top competitors of Cellipont?

Cellipont's top competitors include Mytos, Oxford BioMedica and Pluri. Among them, Pluri secured the most recent funding round in March, 2026.

Cellipont - 2026 Company Profile, Funding & Competitors

Cellipont is an acquired company based in Poway (United States), founded in 2002. It operates as a CDMO offers cell therapy development services. Cellipont has raised an undisclosed amount in funding. The company has 97 active competitors, including 21 funded and 16 that have exited. Its top competitors include companies like Mytos, Oxford BioMedica and Pluri.

Company Details

Website: cellipont.com
Social

Key Metrics

Founded Year

2002

Location

Poway, United States

Stage

Acquired

Latest Funding Round

Conventional Debt, Mar 21, 2023, $*****

Investors

Orbimed

Ranked

18^th among 97 active competitors

Employee Count

101 as on Apr 30, 2026

Similar Companies

Mytos & 105 more

Exit Details

Acquired by Great Point Partners (Jan 13, 2022)

View Cellipont's full profile

Cellipont got acquired by Great Point Partners on Jan 13, 2022.

Click here to take a look at Cellipont's acquisition in detail

Cellipont has raised funding over 1 round. Its latest funding round was a Conventional Debt round on Mar 21, 2023 for $*****. 1 investor participated in its latest round. Cellipont has 1 institutional investor.

Here is the list of recent funding rounds of Cellipont:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 21, 2023	4020548	Conventional Debt	5636693	1370932	8668484	4894431

Access funding benchmarks and valuations. Sign up today!

View details of Cellipont's funding rounds and investors

Cellipont's employee count trend

Cellipont has 101 employees as of Apr 26. Here is Cellipont's employee count trend over the years:

Uncover Cellipont's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellipont include Mytos, Oxford BioMedica and Pluri. Here is the list of Top 10 competitors of Cellipont, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Mytos 2016, London (United Kingdom), Series A	Provider of automated cell manufacturing for regenerative medicine applications	$19M	Buckley Ventures, Artis Ventures & 6 others	61/100
2nd	Oxford BioMedica 1995, Oxford (United Kingdom), Public	Developer of gene therapies for the treatment of multiple diseases	-	Vitruvian Partners, Oxford University Innovation ... & 6 others	60/100
3rd	Pluri 2003, Haifa (Israel), Public	Developer of three-dimensional cell expansion platforms for various industries	-	Merchant Adventure Investment Advisors, Europa ... & 2 others	54/100
4th	Genflow Biosciences 2020, Charleroi (Belgium), Public	CDMO focused on developing of gene therapies to reverse the aging processes	-	Wallonia, Longevitytech.fund & 1 others	53/100
5th	Orgenesis 2008, Germantown (United States), Public	Developer of cell and gene therapies for multiple disorders	-	Kodiak Capital, Boundary Holding & 4 others	50/100
6th	MaSTherCell 2011, Charleroi (Belgium), Acquired	Provider of services for the development of cell therapy products	$17.4M	Great Point Partners, SFPI & 5 others	49/100
7th	eXmoor 2004, Bristol (United Kingdom), Series A	Provider of cell & gene therapautic services for biopharmaceutical sector	$51.7M	MVM, Kineticos	48/100
8th	Exothera 2020, Brussels (Belgium), Funding Raised	CDMO focused on provider of clinical trial services to biopharma sector	-	Europa	47/100
9th	Porton Advanced Solutions 2018, Suzhou (China), Series B	Provider of cell & gene therapy, discovery research, analytical development, and testing services	$80M	China Merchants Capital, HM Capital & 6 others	46/100
10th	Advent BioServices 2016, Sawston (United Kingdom), Acquired	CDMO focused on manufacturing of cell based therapy products	-	-	46/100
18th	Cellipont 2002, Poway (United States), Acquired	CDMO offers cell therapy development services	-	Orbimed	40/100